Cadila Healthcare advances on acquiring Melgain lotion from Issar Pharma

09 Aug 2016 Evaluate

Cadila Healthcare is currently trading at Rs. 377.80, up by 4.05 points or 1.08% from its previous closing of Rs. 373.75 on the BSE.

The scrip opened at Rs. 376.10 and has touched a high and low of Rs. 379.00 and Rs. 372.55 respectively. So far 15,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 295.50 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 379.90 and Rs. 342.00 respectively. The current market cap of the company is Rs. 38,717.95 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.87% and 8.33% respectively.

Cadila Healthcare has acquired Melgain lotion used for treatment of skin depigmentation from Issar Pharma to strengthen its dermatological portfolio. Melgain will be marketed in India by Liva Healthcare, a specialty division of the group catering to the dermatological segment. Melgain is used for the treatment of Vitiligo, a chronic skin condition characterized by portions of the skin losing their pigment.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.


Zydus Lifesciences Share Price

888.00 2.80 (0.32%)
01-Feb-2026 11:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.00
Dr. Reddys Lab 1225.55
Cipla 1324.50
Zydus Lifesciences 888.00
Lupin 2121.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×